Hepalink Announces Strong Mid-Year Financials

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has reported a robust financial performance for the first half of 2024, with a significant increase in profit attributable to equity holders of the parent by 438.1% compared to the same period in 2023. Revenue and gross profit also saw a healthy rise by 4.5% and 4.2% respectively. Additionally, the firm’s cash reserves improved, with a 24.8% growth in cash and cash equivalents.

For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.